For the Inventor, By the Inventor

Enter assignee name

Zhejiang, China

Hangzhou Solipharma Co., Ltd.

USPTO Granted Patents = 19

% Expired Patents = 52.6

Forward Citations = 9

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Xiaoxia Sheng (19 out of 30 patents)

Xiaohong Sheng (17 out of 28 patents)

Tao Zhu (3 out of 7 patents)

4. Jing Wang (2 out of 8 patents)

5. Yanli Dai (2 out of 2 patents)

6. Jianfeng Zheng (2 out of 3 patents)

7. Yong Tang (2 out of 2 patents)

8. Jian Chen (1 out of 27 patents)

9. Kun Zhao (1 out of 2 patents)

10. Xiaoye Song (1 out of 3 patents)

11. Xiawei Jiang (1 out of 3 patents)

12. Xiangjun Shi (1 out of 2 patents)

13. Yinghua Shao (1 out of 1 patent)

14. Yu Dai (1 out of 1 patent)

19 patents: Sort by Forward Citations

1. 12103925 - Crystal and amorphous form of tolebrutinib, preparation method therefor, and use thereof (2024-10-01),

2. 11919906 - Crystal form of ACP-196 and method of treatment thereof (2024-03-05),

3. 11639341 - Crystal form of tipifarnib and method of treatment thereof (2023-05-02),

4. 11427528 - Fenofibrate crystalline form and manufacturing method thereof (2022-08-30),

5. 11286259 - Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof (2022-03-29),

6. 11236077 - Fruquintinib eutectic crystal, preparation method therefor, composition, and uses thereof (2022-02-01),

7. 11236073 - ODM-201 crystalline form, preparation method therefor, and pharmaceutical composition thereof (2022-02-01),

8. 11208382 - Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof (2021-12-28),

9. 11117875 - Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod (2021-09-14),

10. 11111248 - Crystal form of 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-dihydro-4H-pyrrolo[1,2-B]pyrazole, preparation method therefor and pharmaceutical composition thereof (2021-09-07),

11. 10995083 - Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition (2021-05-04),

12. 10954223 - Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof (2021-03-23),

13. 10954210 - Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof (2021-03-23),

14. 10899770 - Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof (2021-01-26),

15. 10899767 - Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof (2021-01-26),

Company Overview

Hangzhou Solipharma Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in the research, development, and manufacturing of a diverse range of pharmaceutical products. The company focuses on innovative drug formulations and delivery systems, catering to various therapeutic areas. With its headquarters in Zhejiang, China, Solipharma is committed to advancing healthcare solutions through cutting-edge technology and rigorous quality standards, aiming to enhance patient outcomes both locally and globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

19 Patents

#42 in Zhejiang

#1,553 in China

#32,693 in the World

Zhejiang, China

Hangzhou Solipharma Co., Ltd.

Forward Citations = 9

14 inventors:

Xiaoxia Sheng (19 out of 30 patents)

Xiaohong Sheng (17 out of 28 patents)

Tao Zhu (3 out of 7 patents)

4. Jing Wang (2 out of 8 patents)

5. Yanli Dai (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hangzhou Solipharma Co., Ltd.. Retrieved from https://idiyas.com/company/hangzhou-solipharma-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…